25 November 2021>: Clinical Research
Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders
Giovanni Franchin 1ADEF , Nikhitha Mantri 2ABDEF , Maleeha Zahid 2BEF , Haozhe Sun 2BE , Sudharsan R. Gongati 2BE , Diana M. Ronderos 2BE , Snigdha Gadireddy 2BE , Sridhar Chilimuri 2ABDEF*DOI: 10.12659/MSM.934267
Med Sci Monit 2021; 27:e934267
Table 1 Description of each patient’s presenting symptoms, current therapy, follow-up period, and adverse events.
Case | Underlying rheumatological disease | Current Medications | Presenting symptoms | Infusion administered | Adverse events during infusion | Follow-up duration | Adverse events during follow-up period |
---|---|---|---|---|---|---|---|
1 | Psoriasis | LevothyroxineVitamin B12Ibuprofen | Fatigue, body aches, sore throat, ageusia and anosmia | Bamlanivimab | None | 73 days | None |
2 | Systemic lupus erythematosus | OmeprazoleNifedipineAmlodipineDenosumabMycophenolateCalciumVitamin DDuloxetineLosartanPioglitazoneSimvastatinMetforminPancreatic enzymes | Anosmia, ageusia, fatigue, subjective fever and cough | Bamlanivimab | None | 87 days | None |
3 | Sjogren syndrome and Raynaud disease | AspirinMetoprololOlmesartanVitamin EMagnesium | Anosmia, ageusia, fatigue, subjective fever and cough | Casirivimab-imdevimab | None | 111 days | None |
4 | Psoriatic arthritis | IxekizumabDulaglutideParoxetineAmlodipineBenazepril | Myalgia, subjective fever, cough, sore throat, and anosmia | Casirivimab-imdevimab | None | 45 days | None |